MiNK Therapeutics
INKT
33 hedge funds and large institutions have $848K invested in MiNK Therapeutics in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 12 reducing their positions, and 5 closing their positions.
0.02% less ownership
Funds ownership: 0.29% → 0.27% (-0.02%)
3% less funds holding
Funds holding: 34 → 33 (-1)
20% less capital invested
Capital invested by funds: $1.05M → $848K (-$207K)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
75% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$27.7K |
| 2 |
Millennium Management
New York
|
+$18.6K |
| 3 |
Renaissance Technologies
New York
|
+$12.2K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$584 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$111 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$39.5K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$19.8K |
| 3 |
Jane Street
New York
|
-$19.7K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$16.3K |
| 5 |
VF
Virtu Financial
New York
|
-$11K |
INKT Hedge Fund Activity: Q1 2024 in Review
33 of the 6,827 institutional investors tracked by Wall St. Rank reported a position in MiNK Therapeutics (INKT) for Q1 2024, worth a combined $848K — down 20% from $1.05M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of INKT and 4 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 3 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $27.7K. The largest seller was Oracle Investment Management, exiting entirely with an estimated $39.5K sold.
- 33 institutional investors held MiNK Therapeutics (INKT) as of Q1 2024, down from 34 in Q4 2023.
- Funds reported $848K of MiNK Therapeutics stock for Q1 2024, down 20% quarter-over-quarter.
- 4 funds opened new MiNK Therapeutics positions in Q1 2024 and 5 closed out, a net change of -1 holder.
- The largest MiNK Therapeutics buyer in Q1 2024 was Susquehanna International Group, an estimated $27.7K added.
- The largest MiNK Therapeutics seller in Q1 2024 was Oracle Investment Management, an estimated $39.5K sold.
Based on aggregated 13F filings for Q1 2024.